Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma...

    Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over labelling issue

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-09T09:45:05+05:30  |  Updated On 9 Sept 2019 9:45 AM IST
    Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over labelling issue

    The reason for the recall of lipid-lowering Simvastatin tablets is "Labeling; incorrect or missing lot and/or exp date; some bottles labelled with lot number 05318054B instead of 05318034B," Aurobindo Pharma added.


    New Delhi: The US arm of drug major Aurobindo Pharma is recalling 2,352 bottles of lipid-lowering Simvastatin tablets from the American market, the latest enforcement report of the US health regulator said.


    Aurobindo Pharma USA Inc is recalling 2,352/1,000 count bottles of Simvastatin tablets USP 40 mg manufactured by Aurolife Pharma LLC, the United States Food and Drug Administration (USFDA) said in its Enforcement Report.


    The voluntary ongoing nationwide recall is a class III recall, it added.


    Read Also: Aurobindo Pharma, Shanghai LongJin sign deal to form JV in China


    The product was distributed nationwide by three major distributors who may have further distributed the product, the report said.


    The reason for the recall is "Labeling; incorrect or missing lot and/or exp date; some bottles labelled with lot number 05318054B instead of 05318034B," it added.


    As per the USFDA, a class III recall is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences".


    Read Also: 2 dead, 1 injured after fire engulfed Aurobindo Pharma power plant in Andhra Pradesh

    AurobindoAurobindo PharmaAurolife PharmaClass 3 recallHealthcarelipid druglipid lowering tabletspharmapharma companypharma newspharma news indiasimvastatinUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok